Puma Biotechnology, Inc. (PBYI)
10.76
+0.55
(+5.39%)
USD |
NASDAQ |
Oct 20, 16:00
11.11
+0.35
(+3.25%)
After-Hours: 07:08
Puma Biotechnology Research and Development Expense (TTM) : 71.44M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 71.44M |
| March 31, 2026 | 68.00M |
| December 31, 2025 | 62.07M |
| September 30, 2025 | 60.40M |
| June 30, 2025 | 57.03M |
| March 31, 2025 | 55.21M |
| December 31, 2024 | 54.94M |
| September 30, 2024 | 52.64M |
| June 30, 2024 | 51.54M |
| March 31, 2024 | 51.26M |
| December 31, 2023 | 50.38M |
| September 30, 2023 | 51.29M |
| June 30, 2023 | 51.10M |
| March 31, 2023 | 49.71M |
| December 31, 2022 | 52.24M |
| September 30, 2022 | 52.62M |
| June 30, 2022 | 60.21M |
| March 31, 2022 | 66.88M |
| December 31, 2021 | 71.87M |
| September 30, 2021 | 81.90M |
| June 30, 2021 | 86.41M |
| March 31, 2021 | 92.46M |
| December 31, 2020 | 97.69M |
| September 30, 2020 | 103.69M |
| June 30, 2020 | 110.37M |
| Date | Value |
|---|---|
| March 31, 2020 | 122.54M |
| December 31, 2019 | 132.81M |
| September 30, 2019 | 141.01M |
| June 30, 2019 | 147.34M |
| March 31, 2019 | 153.73M |
| December 31, 2018 | 164.93M |
| September 30, 2018 | 176.73M |
| June 30, 2018 | 189.87M |
| March 31, 2018 | 199.88M |
| December 31, 2017 | 207.76M |
| September 30, 2017 | 213.96M |
| June 30, 2017 | 216.43M |
| March 31, 2017 | 217.39M |
| December 31, 2016 | 222.80M |
| September 30, 2016 | 218.90M |
| June 30, 2016 | 218.85M |
| March 31, 2016 | 224.01M |
| December 31, 2015 | 208.53M |
| September 30, 2015 | 195.53M |
| June 30, 2015 | 175.70M |
| March 31, 2015 | 151.32M |
| December 31, 2014 | 122.89M |
| September 30, 2014 | 96.39M |
| June 30, 2014 | 76.37M |
| March 31, 2014 | 51.81M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Anika Therapeutics, Inc. | 27.45M |
| Arcutis Biotherapeutics, Inc. | 91.04M |
| Olema Pharmaceuticals, Inc. | 190.19M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |